MIJ821の新興薬剤に関する洞察と市場予測：2032年

当レポートでは、主要7ヶ国におけるMIJ821市場について調査し、市場の概要とともに、2027年から2032年までの売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 治療抵抗性鬱病におけるMIJ821の概要

• 製品の詳細
• 臨床開発
  • 臨床試験
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（後期段階の新興治療薬）

第4章 MIJ821の市場評価

• 治療抵抗性鬱病におけるMIJ821の市場展望
• 主要7ヶ国市場分析
  • 治療抵抗性鬱病の主要7ヶ国におけるMIJ821の市場規模
• 国別市場分析
  • 米国市場規模
  • ドイツ
  • 英国

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

• 参考文献
• レポートの調査手法

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: MIJ821, Clinical Trial Description, 2022
• Table 2: MIJ821, General Description, 2022
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: MIJ821 Market Size in the 7MM, in USD million (2019-2032)
• Table 5: MIJ821 Market Size in the US, in USD million (2019-2032)
• Table 6: MIJ821 Market Size in Germany, in USD million (2019-2032)
• Table 7: MIJ821 Market Size in France, in USD million (2019-2032)
• Table 8: MIJ821 Market Size in Italy, in USD million (2019-2032)
• Table 9: MIJ821 Market Size in Spain, in USD million (2019-2032)
• Table 10: MIJ821 Market Size in the UK, in USD million (2019-2032)
• Table 11: MIJ821 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: MIJ821 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: MIJ821 Market Size in the United States, USD million (2019-2032)
• Figure 3: MIJ821 Market Size in Germany, USD million (2019-2032)
• Figure 4: MIJ821 Market Size in France, USD million (2019-2032)
• Figure 5: MIJ821 Market Size in Italy, USD million (2019-2032)
• Figure 6: MIJ821 Market Size in Spain, USD million (2019-2032)
• Figure 7: MIJ821 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: MIJ821 Market Size in Japan, USD million (2019-2032)

"MIJ821, Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MIJ821 for Treatment Resistant Depression in seven major markets. A detailed picture of the MIJ821 for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the MIJ821 for Treatment Resistant Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MIJ821 market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.

Drug Summary:

MIJ821 is a potent, subtype-selective NMDAr 2B receptor and acts as the negative allosteric modulator (NAM). The product was discovered by Cadent Therapeutics to produce rapid ketamine relief to patients without ketamine like side-effects. Later, Cadent Therapeutics licensed the intellectual property for NMDA receptors compounds (MIJ821) that selectively modulate NR2B to Novartis exclusively. Currently, Novartis is conducting the Phase II trial for Treatment Resistant Depression.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MIJ821 description, mechanism of action, dosage and administration, research and development activities in Treatment Resistant Depression.
• Elaborated details on MIJ821 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MIJ821 research and development activities in Treatment Resistant Depression across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MIJ821.
• The report contains forecasted sales of MIJ821 for Treatment Resistant Depression till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Treatment Resistant Depression.
• The report also features the SWOT analysis with analyst views for MIJ821 in Treatment Resistant Depression.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MIJ821 Analytical Perspective by DelveInsight

• In-depth MIJ821 Market Assessment

This report provides a detailed market assessment of MIJ821 for Treatment Resistant Depression in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• MIJ821 Clinical Assessment

The report provides the clinical trials information of MIJ821 for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Treatment Resistant Depression is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MIJ821 dominance.
• Other emerging products for Treatment Resistant Depression are expected to give tough market competition to MIJ821 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MIJ821 in Treatment Resistant Depression.
• Our in-depth analysis of the forecasted sales data of MIJ821 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MIJ821 in Treatment Resistant Depression.

Key Questions

• What is the product type, route of administration and mechanism of action of MIJ821?
• What is the clinical trial status of the study related to MIJ821 in Treatment Resistant Depression and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MIJ821 development?
• What are the key designations that have been granted to MIJ821 for Treatment Resistant Depression?
• What is the forecasted market scenario of MIJ821 for Treatment Resistant Depression?
• What are the forecasted sales of MIJ821 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to MIJ821 for Treatment Resistant Depression?
• Which are the late-stage emerging therapies under development for the treatment of Treatment Resistant Depression?

Table of Contents

1. Report Introduction

2. MIJ821 overview in Treatment Resistant Depression

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical Studies
  • 2.2.2. Clinical Trials Information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. MIJ821 Market Assessment

• 4.1. Market Outlook of MIJ821 in Treatment Resistant Depression
• 4.2. 7MM Market Analysis
  • 4.2.1. Market Size of MIJ821 in the 7MM for Treatment Resistant Depression
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of MIJ821 in the United States for Treatment Resistant Depression
  • 4.3.2. Market Size of MIJ821 in Germany for Treatment Resistant Depression
  • 4.3.3. Market Size of MIJ821 in France for Treatment Resistant Depression
  • 4.3.4. Market Size of MIJ821 in Italy for Treatment Resistant Depression
  • 4.3.5. Market Size of MIJ821 in Spain for Treatment Resistant Depression
  • 4.3.6. Market Size of MIJ821 in the United Kingdom for Treatment Resistant Depression
  • 4.3.7. Market Size of MIJ821 in Japan for Treatment Resistant Depression

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options